Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 428

1.

Endoscopic resection for patients with mucosal adenocarcinoma of the esophagus.

Knabe M, May A, Ell C.

Minerva Gastroenterol Dietol. 2016 Dec;62(4):281-295.

PMID:
27652683
2.

Portal vein leiomyosarcoma: a case report and review of the literature.

Gohrbandt AE, Hansen T, Ell C, Heinrich SS, Lang H.

BMC Surg. 2016 Sep 1;16(1):60. doi: 10.1186/s12893-016-0174-x. Review.

3.

[Safety of sedation during gastroscopy and colonoscopy in low-risk patients - results of a retrospective subgroup analysis of a registry study including over 170 000 endoscopies].

Behrens A, Ell C; Studiengruppe ALGK-ProSed..

Z Gastroenterol. 2016 Aug;54(8):733-9. doi: 10.1055/s-0042-108655. German.

PMID:
27529524
4.

Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON).; Esophageal Adenocarcinoma GenEtics Consortium (EAGLE).; Wellcome Trust Case Control Consortium 2 (WTCCC2)., Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RG, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WH, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J.

Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6.

5.

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR.

BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.

6.

Perioperative and Palliative Chemotherapy for Esophageal Cancer.

Behrens A, Ell C, Lordick F.

Viszeralmedizin. 2015 Oct;31(5):341-6. doi: 10.1159/000438470. Review.

7.

Endoscopic Therapy of Early Carcinoma of the Oesophagus.

Knabe M, May A, Ell C.

Viszeralmedizin. 2015 Oct;31(5):320-5. doi: 10.1159/000441075. Review.

8.

Diagnosis and Treatment of Oesophageal Carcinoma: Changes in Every Respect.

Ell C, Lorenz D.

Viszeralmedizin. 2015 Oct;31(5):314. doi: 10.1159/000441536. No abstract available.

9.

Early-stage adenocarcinoma of the esophagus with mid to deep submucosal invasion (pT1b sm2-3): the frequency of lymph-node metastasis depends on macroscopic and histological risk patterns.

Manner H, Wetzka J, May A, Pauthner M, Pech O, Fisseler-Eckhoff A, Stolte M, Vieth M, Lorenz D, Ell C.

Dis Esophagus. 2016 Mar 8. doi: 10.1111/dote.12462. [Epub ahead of print]

PMID:
26952572
10.

The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk.

Becker J, May A, Gerges C, Anders M, Schmidt C, Veits L, Noder T, Mayershofer R, Kreuser N, Manner H, Venerito M, Hofer JH, Lyros O, Ahlbrand CJ, Arras M, Hofer S, Heinrichs SK, Weise K, Hess T, Böhmer AC, Kosiol N, Kiesslich R, Izbicki JR, Hölscher AH, Bollschweiler E, Malfertheiner P, Lang H, Moehler M, Lorenz D, Ott K, Schmidt T, Nöthen MM, Hackelsberger A, Schumacher B, Pech O, Vashist Y, Vieth M, Weismüller J, Knapp M, Neuhaus H, Rösch T, Ell C, Gockel I, Schumacher J.

Cancer Med. 2016 May;5(5):888-91. doi: 10.1002/cam4.641.

11.

Erratum to: Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus.

Manner H, May A, Kouti I, Pech O, Vieth M, Ell C.

Surg Endosc. 2016 Apr;30(4):1371. doi: 10.1007/s00464-015-4741-5. No abstract available.

PMID:
26721690
12.

Verrucous Oesophageal Carcinoma: Single Case Report and Case Series Including 15 Patients - Issues for Consideration of Therapeutic Strategies.

Behrens A, Stolte M, Pech O, May A, Ell C.

Viszeralmedizin. 2014 Oct;30(5):346-52. doi: 10.1159/000368270.

13.

Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma.

Becker J, May A, Gerges C, Anders M, Veits L, Weise K, Czamara D, Lyros O, Manner H, Terheggen G, Venerito M, Noder T, Mayershofer R, Hofer JH, Karch HW, Ahlbrand CJ, Arras M, Hofer S, Mangold E, Heilmann-Heimbach S, Heinrichs SK, Hess T, Kiesslich R, Izbicki JR, Hölscher AH, Bollschweiler E, Malfertheiner P, Lang H, Moehler M, Lorenz D, Müller-Myhsok B, Ott K, Schmidt T, Whiteman DC, Vaughan TL, Nöthen MM, Hackelsberger A, Schumacher B, Pech O, Vashist Y, Vieth M, Weismüller J, Neuhaus H, Rösch T, Ell C, Gockel I, Schumacher J.

Cancer Med. 2015 Nov;4(11):1700-4. doi: 10.1002/cam4.500.

14.

Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.

Hatlebakk JG, Zerbib F, Bruley des Varannes S, Attwood SE, Ell C, Fiocca R, Galmiche JP, Eklund S, Långström G, Lind T, Lundell LR; LOTUS Study Group..

Clin Gastroenterol Hepatol. 2016 May;14(5):678-85.e3. doi: 10.1016/j.cgh.2015.07.025.

PMID:
26226096
15.

Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.

Pohl H, Pech O, Arash H, Stolte M, Manner H, May A, Kraywinkel K, Sonnenberg A, Ell C.

Gut. 2016 Feb;65(2):196-201. doi: 10.1136/gutjnl-2015-309220.

PMID:
26113177
16.

Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus.

Manner H, May A, Kouti I, Pech O, Vieth M, Ell C.

Surg Endosc. 2016 Apr;30(4):1364-70. doi: 10.1007/s00464-015-4336-1. Erratum in: Surg Endosc. 2016 Apr;30(4):1371.

PMID:
26104794
17.

[Detection of early neoplasia in Barrett's oesophagus: focus attention on index endoscopy in short-segment-Barrett's oesophagus with random biopsies].

Behrens A, Pech O, Wuthnow E, Manner H, Pohl J, May A, Ell C.

Z Gastroenterol. 2015 Jun;53(6):568-72. doi: 10.1055/s-0034-1399177. German.

PMID:
26075367
18.

Endoscopic therapy in early adenocarcinomas (Barrett's cancer) of the esophagus.

Knabe M, May A, Ell C.

J Dig Dis. 2015 Jul;16(7):363-9. doi: 10.1111/1751-2980.12264. Review.

PMID:
26031930
19.

BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J, Aldulaimi D, Ho KY, Odze R, Meltzer SJ, Quigley E, Gittens S, Watson P, Zaninotto G, Iyer PG, Alexandre L, Ang Y, Callaghan J, Harrison R, Singh R, Bhandari P, Bisschops R, Geramizadeh B, Kaye P, Krishnadath S, Fennerty MB, Manner H, Nason KS, Pech O, Konda V, Ragunath K, Rahman I, Romero Y, Sampliner R, Siersema PD, Tack J, Tham TC, Trudgill N, Weinberg DS, Wang J, Wang K, Wong JY, Attwood S, Malfertheiner P, MacDonald D, Barr H, Ferguson MK, Jankowski J; BOB CAT Consortium..

Am J Gastroenterol. 2015 May;110(5):662-82; quiz 683. doi: 10.1038/ajg.2015.55. Review. Erratum in: Am J Gastroenterol. 2015 Jun;110(6):943.

20.

Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.

Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, Långström G, Jahreskog M, Eklund S, Lind T, Lundell L.

Aliment Pharmacol Ther. 2015 Jun;41(11):1162-74. doi: 10.1111/apt.13194.

Items per page

Supplemental Content

Loading ...
Support Center